Evidence map›Paper›PMID 35887642›Full record

ArticleJournal of personalized medicine2022

Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System.

Loren Saulsberry, Lavisha Singh, Jaclyn Pruitt, Christopher Ward, Dyson T Wake, Robert D Gibbons, David O Meltzer, Peter H O'Donnell, Wanda Cruz-Knight, Peter J Hulick and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Loren SaulsberryDepartment of Public Health Sciences, The University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-0325-2329
Lavisha SinghDepartment of Biostatistics, NorthShore University HealthSystem, Evanston, IL 60201, USA.
Jaclyn PruittOutcomes Research Network, NorthShore University HealthSystem, Evanston, IL 60201, USA.
Christopher WardCenter for Personalized Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA.
Dyson T WakeCenter for Personalized Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA.
Robert D GibbonsDepartment of Public Health Sciences, The University of Chicago, Chicago, IL 60637, USA.
David O MeltzerSection of Hospital Medicine, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Peter H O'DonnellCenter for Personalized Therapeutics, The University of Chicago, Chicago, IL 60637, USA.
Wanda Cruz-KnightDepartment of Family Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA.
Peter J HulickCenter for Personalized Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA.ORCID 0000-0001-8397-4078
Henry M DunnenbergerCenter for Personalized Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA.ORCID 0000-0002-6211-1713
Sean P DavidOutcomes Research Network, NorthShore University HealthSystem, Evanston, IL 60201, USA.ORCID 0000-0002-4922-2603
NorthShore University HealthSystem · USChicago Department of Public Health · USUniversity of Chicago · US

Funding

The Institute for Translational MedicineUL1TR002389 · NCATS · UNIVERSITY OF CHICAGO · PI Joshua J Jacobs, DAVID O MELTZER · 2017 to 2026
$71.6M
Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
Health Equity and Risk Communication in PharmacogenomicsK08HG011505 · NHGRI · UNIVERSITY OF CHICAGO · PI SAULSBERRY, LOREN · 2020 to 2024
$836k
NCATS NIH HHS UL1 TR002389NHGRI NIH HHS K08 HG011505NIEHS NIH HHS P30 ES027792NIH HHS K08 HG011505NIH HHS UL1 TR002389
6 · The paper itself

Abstract

The present study builds on our prior work that demonstrated an association between pharmacogenetic interactions and 90-day readmission. In a substantially larger, more diverse study population of 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel, we included additional covariates to evaluate aggregate contribution of social determinants and medical comorbidity with the presence of identified gene-x-drug interactions to moderate 90-day hospital readmission (primary outcome). Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7.66, 95% confidence interval 5.45−10.77) (p < 0.0001), major comorbidities (5+ comorbidities, OR 3.36, 2.61−4.32) (p < 0.0001), age (65 + years, OR = 2.35, 1.77−3.12) (p < 0.0001), unemployment (OR = 2.19, 1.88−2.64) (p < 0.0001), Black/African-American race (OR 2.12, 1.47−3.07) (p < 0.0001), median household income (OR = 1.63, 1.03−2.58) (p = 0.035), male gender (OR = 1.47, 1.21−1.80) (p = 0.0001), and one or more gene-x-drug interaction (defined as a prescribed CPIC medication for a patient with a corresponding actionable pharmacogenetic variant) (OR = 1.41, 1.18−1.70). Health insurance was not associated with risk of 90-day readmission. Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model. The odds of 90-day readmission for patients with one or more identified gene-x-drug interactions after adjustment for these covariates was attenuated by 10% (OR = 1.31, 1.08−1.59) (p = 0.006). Although the interaction between race and gene-x-drug interactions was not statistically significant, White patients were more likely to have a gene-x-drug interaction (35.2%) than Black/African-American patients (25.9%) who were not readmitted (p < 0.0001). These results highlight the major contribution of social determinants and medical complexity to risk for hospital readmission, and that these determinants may modify the effect of gene-x-drug interactions on rehospitalization risk.

Indexed as

personalized medicinepharmacogeneticsprimary caresocial determinants of health (SDoH)

Identifiers

PMID35887642
PMCPMC9319564
OpenAlexW4285733392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.